(2)
Sandusky, Ohio (Newsfile Corp. - February 4, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today revealed plans to expand its nutraceutical product reach. The company plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled, METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
In addition to PAOG s ongoing efforts to develop a pharmaceutical treatment for COPD, the company has announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical pr
PAO Group, Inc.: PAOG Confirms CBD Nutraceutical Development and Distribution Partners
Sandusky, Ohio (Newsfile Corp. - February 2, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed its plans to develop and distribute cannabis nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as partners.
PAOG recently engaged with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS IN
PAOG Takes Next Step To Produce Cannabis Nutraceuticals
News provided by
Share this article
Share this article
SANDUSKY, Ohio, Jan. 27, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today announced moving forward with its initiative to produce cannabis nutraceuticals.
PAOG recently engaged with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
PAOG CBD Nutraceuticals Underdevelopment To Be Distributed Through USMJ
News provided by
Share this article
Share this article
SANDUSKY, Ohio, Jan. 27, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today announced moving forward with its initiative to produce cannabis nutraceuticals. PAOG added that the nutraceuticals, in addition to other distribution channels, will be available through the North American Cannabis, Inc. (
USOTC: USMJ) ecommerce site www.usjm.com.
PAOG recently engaged with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
News Category Global Banking & Finance Reviews
CHSI Technologies Continues Delivering on Business Momentum and Product Innovation with Record Growth Numbers in 2020
CHSI Technologies Continues Delivering on Business Momentum and Product Innovation with Record Growth Numbers in 2020 CHSI Technologies (CHSI or the Company), the market-leading SaaS InsureTech firm for policy and claims lifecycle management, billing, decision support and analytics announced record financial results and exponential sales growth in 2020. Post CHSIs majority recapitalization in Q4 2019 by Bow River Capitals SaaS Growth Equity Fund, CHSI executed on its strategic vision and operating plan; highlighted by releasing modern SaaS Claims and Portal modules, aggressively scaling each business unit, and re-engineering the Companys go-to-market engine.